🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Copenhagen Heart Failure With Preserved Ejection Fraction

Recruitingn/aAges 50 Years - 89 YearsAllTor Biering-Sørensen
NCT06685237 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Residence in the Capital Region of Denmark 2. Age ≥ 50 years 3. At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one): * Hypertension * Diabetes mellitus * Chronic kidney disease * Atrial fibrillation * BMI \> 25 kg/m2 * Previous heart valve surgery * Ischemic heart disease * Obstructive sleep apnea * Furosemide 40 mg Exclusion Criteria: 1. Age ≥ 90 years 2. Prevalent HF 3. Dementia 4. Nursing home 5. Amyloidosis 6. Hemodialysis 7. Cancer diagnosed within the past 5 years (skin cancer not included) 8. Prior solid organ transplantation 9. Lung disease defined as any of the following: * World Health Organization Group 1 pulmonary hypertension * Chronic pulmonary embolism * Lung fibrosis * Chronic obstructive pulmonary disease (COPD) * Home oxygen
💊

What it tests

  • Not listed
📍

Where

1 site
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital
Hellerup, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy